# Maintenance and consolidation in lymphoma: where it works and where it does not

Source: https://onco.cc/terms/lymphoma-tx-maintenance/  
OnCo record `lymphoma-tx-maintenance` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

After the main treatment, some lymphomas are given a lower-intensity drug for months or years to hold the remission. It lengthens remission in follicular and mantle cell lymphoma but has never been shown to lengthen life, so it is a trade against two years of infusions and infections.

## Summary

Follicular lymphoma. PRIMA randomised 1,018 responders after first-line immunochemotherapy to two years of rituximab every eight weeks or observation. At the final analysis, median progression-free survival was 10.5 years with maintenance against 4.1 years with observation (hazard ratio 0.61), but ten-year overall survival was about 80 per cent in both arms. Maintenance therefore buys time to the next treatment and costs two years of infusions, neutropenia and a higher infection rate. Many units now discuss it as a choice.

Mantle cell lymphoma. LyMa randomised 240 patients under 66 after autologous transplant to three years of rituximab every two months or observation: four-year event-free survival 79 against 61 per cent, and, unusually for maintenance, overall survival was improved. Rituximab maintenance after transplant is standard in Europe and the United Kingdom.

Diffuse large B-cell lymphoma. Maintenance has repeatedly failed to change survival. REMARC gave lenalidomide or placebo for two years to 650 responders aged 60 to 80 after R-CHOP: progression-free survival improved (hazard ratio 0.708) but overall survival did not (hazard ratio 1.218), and grade 3 or 4 neutropenia was 56 against 22 per cent. Rituximab maintenance after R-CHOP has never shown benefit.

Hodgkin lymphoma. AETHERA gave brentuximab vedotin or placebo after autologous transplant to 329 patients at high risk of relapse and improved progression-free survival (median 42.9 against 24.1 months, hazard ratio 0.57); this is consolidation of a transplant rather than open-ended maintenance, and it is standard for the high-risk group.

The honest summary: maintenance treats the scan, not always the person. It is the right choice for someone who values a longer interval before the next line, and the wrong one for someone who wants to stop treatment and be well.

## Fields

- Kind: Term
- Last checked: 2026-09-29
- Also known as: Rituximab maintenance; Lenalidomide maintenance; Brentuximab consolidation

## Sources

- PRIMA: two years of rituximab maintenance in follicular lymphoma, Lancet 2011: https://doi.org/10.1016/S0140-6736(10)62175-7
- PRIMA final analysis at nine years, Journal of Clinical Oncology 2019: https://doi.org/10.1200/JCO.19.01073
- LyMa: rituximab after autologous transplant in mantle cell lymphoma, New England Journal of Medicine 2017: https://doi.org/10.1056/NEJMoa1701769
- REMARC: lenalidomide maintenance after R-CHOP, Journal of Clinical Oncology 2017: https://doi.org/10.1200/JCO.2017.72.6984

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/)
- terms: [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/), [Lymphoma treatments that did not work: the negative trials worth knowing](https://onco.cc/terms/lymphoma-tx-failed-and-negative/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest](https://onco.cc/terms/lymphoma-tx-regimen-alphabet/)
- trials: [AETHERA](https://onco.cc/trials/aethera/)

---
JSON: https://onco.cc/api/v1/entities/lymphoma-tx-maintenance.json